Radical prostatectomy as radical cure of prostate cancer in a high-risk group: A single-institution experience

This study aimed to evaluate the possibility of performing radical prostatectomy (RP) alone to achieve radical cure of prostate cancer in a high-risk group. Between August 1998 and December 2008, 436 Japanese patients underwent antegrade RP following the exclusion of 139 patients. According to the D...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Molecular and clinical oncology 2013-03, Vol.1 (2), p.337-342
Hauptverfasser: FURUBAYASHI, NOBUKI, NAKAMURA, MOTONOBU, HISHIKAWA, KEN, FUKUDA, ATSUSHI, MATSUMOTO, TAKASHI, NISHIYAMA, KENICHI, YAMANAKA, TAKEHARU, HASEGAWA, YOSHIHIRO
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 342
container_issue 2
container_start_page 337
container_title Molecular and clinical oncology
container_volume 1
creator FURUBAYASHI, NOBUKI
NAKAMURA, MOTONOBU
HISHIKAWA, KEN
FUKUDA, ATSUSHI
MATSUMOTO, TAKASHI
NISHIYAMA, KENICHI
YAMANAKA, TAKEHARU
HASEGAWA, YOSHIHIRO
description This study aimed to evaluate the possibility of performing radical prostatectomy (RP) alone to achieve radical cure of prostate cancer in a high-risk group. Between August 1998 and December 2008, 436 Japanese patients underwent antegrade RP following the exclusion of 139 patients. According to the D'Amico criteria, the low-, intermediate- and high-risk groups comprised 63, 122 and 112 patients, respectively. Twenty-five patients who were classified into the high-risk group based only on T2c stage, were evaluated as a separate intermediate/high-risk group. Results of the multivariate analysis revealed that of the preoperative characteristics only a biopsy Gleason score was a significant predictor in patients with and without PSA failure (P=0.017). After a median follow-up period of 60 months, the PSA failure-free rates in the low-, intermediate-, high- and intermediate/high-risk groups were 96.5, 92.2, 76.8 and 95.0%, respectively. No statistically significant difference was detected in the high- and intermediate/high-risk groups (P=0.064). Thus, patients classified into the high-risk group based on cT2 stage only, are considered to be potentially eligible for radical treatment by surgery alone, and should not be evaluated as high-risk patients.
doi_str_mv 10.3892/mco.2012.39
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3956272</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1826593599</sourcerecordid><originalsourceid>FETCH-LOGICAL-c371t-734903f4147a27c1c88fb59ad1d49cce5c088f1d60e3f7a2d38fe196a7444fec3</originalsourceid><addsrcrecordid>eNpdkc1rFTEUxYMottSu3EvAhYWS13zNZOJCKMWqUBCKrkOaufNe6kwyJhlp_3tT3nNQs7nh3t89nOQg9JrRjeg0v5hc3HDK-EboZ-iYU6mJlq1-vt4beoROc76n9WhFeaNfoiMuW6mZ4sco3NreOzviOcVcbAFX4vSIbcbpMHBLAhyHFcDOBgcJ-4At3vntjiSff-Btisv8Hl_i7MN2BOJDLr4sxceA4WGG5KGuvUIvBjtmOD3UE_T9-uO3q8_k5uunL1eXN8QJxQpRQmoqBsmkslw55rpuuGu07VkvtXPQOFo7rG8piKEivegGYLq1Sko5gBMn6MNed17uJugdhJLsaObkJ5seTbTe_DsJfme28ZcRumm54lXg7CCQ4s8FcjGTzw7G0QaISzas422jRaN1Rd_-h97HJYX6PMO04LIRvFWVOt9Trv5jTjCsZhg1T1GaGqV5irJ6qPSbv_2v7J_gKvBuD-TZht73Ma9M1SGUEcoJFUKJ34KIqJQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1932453267</pqid></control><display><type>article</type><title>Radical prostatectomy as radical cure of prostate cancer in a high-risk group: A single-institution experience</title><source>Spandidos Publications Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>FURUBAYASHI, NOBUKI ; NAKAMURA, MOTONOBU ; HISHIKAWA, KEN ; FUKUDA, ATSUSHI ; MATSUMOTO, TAKASHI ; NISHIYAMA, KENICHI ; YAMANAKA, TAKEHARU ; HASEGAWA, YOSHIHIRO</creator><creatorcontrib>FURUBAYASHI, NOBUKI ; NAKAMURA, MOTONOBU ; HISHIKAWA, KEN ; FUKUDA, ATSUSHI ; MATSUMOTO, TAKASHI ; NISHIYAMA, KENICHI ; YAMANAKA, TAKEHARU ; HASEGAWA, YOSHIHIRO</creatorcontrib><description>This study aimed to evaluate the possibility of performing radical prostatectomy (RP) alone to achieve radical cure of prostate cancer in a high-risk group. Between August 1998 and December 2008, 436 Japanese patients underwent antegrade RP following the exclusion of 139 patients. According to the D'Amico criteria, the low-, intermediate- and high-risk groups comprised 63, 122 and 112 patients, respectively. Twenty-five patients who were classified into the high-risk group based only on T2c stage, were evaluated as a separate intermediate/high-risk group. Results of the multivariate analysis revealed that of the preoperative characteristics only a biopsy Gleason score was a significant predictor in patients with and without PSA failure (P=0.017). After a median follow-up period of 60 months, the PSA failure-free rates in the low-, intermediate-, high- and intermediate/high-risk groups were 96.5, 92.2, 76.8 and 95.0%, respectively. No statistically significant difference was detected in the high- and intermediate/high-risk groups (P=0.064). Thus, patients classified into the high-risk group based on cT2 stage only, are considered to be potentially eligible for radical treatment by surgery alone, and should not be evaluated as high-risk patients.</description><identifier>ISSN: 2049-9450</identifier><identifier>EISSN: 2049-9469</identifier><identifier>DOI: 10.3892/mco.2012.39</identifier><identifier>PMID: 24649172</identifier><language>eng</language><publisher>England: D.A. Spandidos</publisher><subject>Biopsy ; Cancer surgery ; Cancer therapies ; Classification ; D'Amico classification ; Health risk assessment ; high-risk group ; Lymphatic system ; Medical prognosis ; Metastasis ; Oncology ; Patients ; Prostate cancer ; prostate-specific antigen failure ; radical prostatectomy ; Surgery ; Urological surgery</subject><ispartof>Molecular and clinical oncology, 2013-03, Vol.1 (2), p.337-342</ispartof><rights>Copyright © 2013, Spandidos Publications</rights><rights>Copyright Spandidos Publications UK Ltd. 2013</rights><rights>Copyright © 2013, Spandidos Publications 2013</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c371t-734903f4147a27c1c88fb59ad1d49cce5c088f1d60e3f7a2d38fe196a7444fec3</citedby><cites>FETCH-LOGICAL-c371t-734903f4147a27c1c88fb59ad1d49cce5c088f1d60e3f7a2d38fe196a7444fec3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3956272/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3956272/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,723,776,780,881,5556,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24649172$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>FURUBAYASHI, NOBUKI</creatorcontrib><creatorcontrib>NAKAMURA, MOTONOBU</creatorcontrib><creatorcontrib>HISHIKAWA, KEN</creatorcontrib><creatorcontrib>FUKUDA, ATSUSHI</creatorcontrib><creatorcontrib>MATSUMOTO, TAKASHI</creatorcontrib><creatorcontrib>NISHIYAMA, KENICHI</creatorcontrib><creatorcontrib>YAMANAKA, TAKEHARU</creatorcontrib><creatorcontrib>HASEGAWA, YOSHIHIRO</creatorcontrib><title>Radical prostatectomy as radical cure of prostate cancer in a high-risk group: A single-institution experience</title><title>Molecular and clinical oncology</title><addtitle>Mol Clin Oncol</addtitle><description>This study aimed to evaluate the possibility of performing radical prostatectomy (RP) alone to achieve radical cure of prostate cancer in a high-risk group. Between August 1998 and December 2008, 436 Japanese patients underwent antegrade RP following the exclusion of 139 patients. According to the D'Amico criteria, the low-, intermediate- and high-risk groups comprised 63, 122 and 112 patients, respectively. Twenty-five patients who were classified into the high-risk group based only on T2c stage, were evaluated as a separate intermediate/high-risk group. Results of the multivariate analysis revealed that of the preoperative characteristics only a biopsy Gleason score was a significant predictor in patients with and without PSA failure (P=0.017). After a median follow-up period of 60 months, the PSA failure-free rates in the low-, intermediate-, high- and intermediate/high-risk groups were 96.5, 92.2, 76.8 and 95.0%, respectively. No statistically significant difference was detected in the high- and intermediate/high-risk groups (P=0.064). Thus, patients classified into the high-risk group based on cT2 stage only, are considered to be potentially eligible for radical treatment by surgery alone, and should not be evaluated as high-risk patients.</description><subject>Biopsy</subject><subject>Cancer surgery</subject><subject>Cancer therapies</subject><subject>Classification</subject><subject>D'Amico classification</subject><subject>Health risk assessment</subject><subject>high-risk group</subject><subject>Lymphatic system</subject><subject>Medical prognosis</subject><subject>Metastasis</subject><subject>Oncology</subject><subject>Patients</subject><subject>Prostate cancer</subject><subject>prostate-specific antigen failure</subject><subject>radical prostatectomy</subject><subject>Surgery</subject><subject>Urological surgery</subject><issn>2049-9450</issn><issn>2049-9469</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>BENPR</sourceid><recordid>eNpdkc1rFTEUxYMottSu3EvAhYWS13zNZOJCKMWqUBCKrkOaufNe6kwyJhlp_3tT3nNQs7nh3t89nOQg9JrRjeg0v5hc3HDK-EboZ-iYU6mJlq1-vt4beoROc76n9WhFeaNfoiMuW6mZ4sco3NreOzviOcVcbAFX4vSIbcbpMHBLAhyHFcDOBgcJ-4At3vntjiSff-Btisv8Hl_i7MN2BOJDLr4sxceA4WGG5KGuvUIvBjtmOD3UE_T9-uO3q8_k5uunL1eXN8QJxQpRQmoqBsmkslw55rpuuGu07VkvtXPQOFo7rG8piKEivegGYLq1Sko5gBMn6MNed17uJugdhJLsaObkJ5seTbTe_DsJfme28ZcRumm54lXg7CCQ4s8FcjGTzw7G0QaISzas422jRaN1Rd_-h97HJYX6PMO04LIRvFWVOt9Trv5jTjCsZhg1T1GaGqV5irJ6qPSbv_2v7J_gKvBuD-TZht73Ma9M1SGUEcoJFUKJ34KIqJQ</recordid><startdate>20130301</startdate><enddate>20130301</enddate><creator>FURUBAYASHI, NOBUKI</creator><creator>NAKAMURA, MOTONOBU</creator><creator>HISHIKAWA, KEN</creator><creator>FUKUDA, ATSUSHI</creator><creator>MATSUMOTO, TAKASHI</creator><creator>NISHIYAMA, KENICHI</creator><creator>YAMANAKA, TAKEHARU</creator><creator>HASEGAWA, YOSHIHIRO</creator><general>D.A. Spandidos</general><general>Spandidos Publications UK Ltd</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20130301</creationdate><title>Radical prostatectomy as radical cure of prostate cancer in a high-risk group: A single-institution experience</title><author>FURUBAYASHI, NOBUKI ; NAKAMURA, MOTONOBU ; HISHIKAWA, KEN ; FUKUDA, ATSUSHI ; MATSUMOTO, TAKASHI ; NISHIYAMA, KENICHI ; YAMANAKA, TAKEHARU ; HASEGAWA, YOSHIHIRO</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c371t-734903f4147a27c1c88fb59ad1d49cce5c088f1d60e3f7a2d38fe196a7444fec3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Biopsy</topic><topic>Cancer surgery</topic><topic>Cancer therapies</topic><topic>Classification</topic><topic>D'Amico classification</topic><topic>Health risk assessment</topic><topic>high-risk group</topic><topic>Lymphatic system</topic><topic>Medical prognosis</topic><topic>Metastasis</topic><topic>Oncology</topic><topic>Patients</topic><topic>Prostate cancer</topic><topic>prostate-specific antigen failure</topic><topic>radical prostatectomy</topic><topic>Surgery</topic><topic>Urological surgery</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>FURUBAYASHI, NOBUKI</creatorcontrib><creatorcontrib>NAKAMURA, MOTONOBU</creatorcontrib><creatorcontrib>HISHIKAWA, KEN</creatorcontrib><creatorcontrib>FUKUDA, ATSUSHI</creatorcontrib><creatorcontrib>MATSUMOTO, TAKASHI</creatorcontrib><creatorcontrib>NISHIYAMA, KENICHI</creatorcontrib><creatorcontrib>YAMANAKA, TAKEHARU</creatorcontrib><creatorcontrib>HASEGAWA, YOSHIHIRO</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Molecular and clinical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>FURUBAYASHI, NOBUKI</au><au>NAKAMURA, MOTONOBU</au><au>HISHIKAWA, KEN</au><au>FUKUDA, ATSUSHI</au><au>MATSUMOTO, TAKASHI</au><au>NISHIYAMA, KENICHI</au><au>YAMANAKA, TAKEHARU</au><au>HASEGAWA, YOSHIHIRO</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Radical prostatectomy as radical cure of prostate cancer in a high-risk group: A single-institution experience</atitle><jtitle>Molecular and clinical oncology</jtitle><addtitle>Mol Clin Oncol</addtitle><date>2013-03-01</date><risdate>2013</risdate><volume>1</volume><issue>2</issue><spage>337</spage><epage>342</epage><pages>337-342</pages><issn>2049-9450</issn><eissn>2049-9469</eissn><abstract>This study aimed to evaluate the possibility of performing radical prostatectomy (RP) alone to achieve radical cure of prostate cancer in a high-risk group. Between August 1998 and December 2008, 436 Japanese patients underwent antegrade RP following the exclusion of 139 patients. According to the D'Amico criteria, the low-, intermediate- and high-risk groups comprised 63, 122 and 112 patients, respectively. Twenty-five patients who were classified into the high-risk group based only on T2c stage, were evaluated as a separate intermediate/high-risk group. Results of the multivariate analysis revealed that of the preoperative characteristics only a biopsy Gleason score was a significant predictor in patients with and without PSA failure (P=0.017). After a median follow-up period of 60 months, the PSA failure-free rates in the low-, intermediate-, high- and intermediate/high-risk groups were 96.5, 92.2, 76.8 and 95.0%, respectively. No statistically significant difference was detected in the high- and intermediate/high-risk groups (P=0.064). Thus, patients classified into the high-risk group based on cT2 stage only, are considered to be potentially eligible for radical treatment by surgery alone, and should not be evaluated as high-risk patients.</abstract><cop>England</cop><pub>D.A. Spandidos</pub><pmid>24649172</pmid><doi>10.3892/mco.2012.39</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2049-9450
ispartof Molecular and clinical oncology, 2013-03, Vol.1 (2), p.337-342
issn 2049-9450
2049-9469
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3956272
source Spandidos Publications Journals; EZB-FREE-00999 freely available EZB journals; PubMed Central
subjects Biopsy
Cancer surgery
Cancer therapies
Classification
D'Amico classification
Health risk assessment
high-risk group
Lymphatic system
Medical prognosis
Metastasis
Oncology
Patients
Prostate cancer
prostate-specific antigen failure
radical prostatectomy
Surgery
Urological surgery
title Radical prostatectomy as radical cure of prostate cancer in a high-risk group: A single-institution experience
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T18%3A37%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Radical%20prostatectomy%20as%20radical%20cure%20of%20prostate%20cancer%20in%20a%20high-risk%20group:%20A%20single-institution%20experience&rft.jtitle=Molecular%20and%20clinical%20oncology&rft.au=FURUBAYASHI,%20NOBUKI&rft.date=2013-03-01&rft.volume=1&rft.issue=2&rft.spage=337&rft.epage=342&rft.pages=337-342&rft.issn=2049-9450&rft.eissn=2049-9469&rft_id=info:doi/10.3892/mco.2012.39&rft_dat=%3Cproquest_pubme%3E1826593599%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1932453267&rft_id=info:pmid/24649172&rfr_iscdi=true